A first in human study of mesothelin-targeting MSLN-TTC

Trial Profile

A first in human study of mesothelin-targeting MSLN-TTC

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Mesothelin targeted thorium-227 conjugate - Bayer (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Apr 2018 New trial record
    • 05 Apr 2018 According to a Bayer media release, company plans to initiate this first in man study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top